retatrutide dosing schedule phase 2 trial FDA Approval Status 2026: Everything We Know So Far Trial Data Dosing Schedule :

GLP-1 receptor agonists have reshaped how clinicians and researchers think about metabolic disease, revealing a hormone system that links appetite, reward, emotion, inflammation and cardiovascular health

We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline

Our study found that patients using semaglutide 1 mg have a higher risk of depression, anxiety, and suicidal ideation when compared with non-semaglutide users, irrespective of age and sex differences

For women with obesity and diabetes, weight loss and improved diabetes control can sometimes help normalize previously irregular menstrual periods and increase fertility, says Dr